Skip to Main Navigation
Skip to Page Content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/10622

Incidence Rates of Nonneoplastic Lesions by Anatomic Site

NTP Experiment-Test: 91014-04         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: CHRONIC                                OLEIC ACID DIETHANOLAMINE CONDENSATE                           Date: 09/23/97
Route: SKIN APPLICATION                                                                                           Time: 09:32:07

                                                          14 WEEK SSAC




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  93-83-4

       Lock Date:  01/02/96

       Cage Range:  All

       Reasons For Removal:    25017 Scheduled Sacrifice

       Removal Date Range:     All

       Treatment Groups:       Include 002    0 MG/KG
                               Include 004    15 MG/KG
                               Include 006    30 MG/KG
                               Include 001    0 MG/KG
                               Include 003    15 MG/KG
                               Include 005    30 MG/KG





























a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 91014-04         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: CHRONIC                                OLEIC ACID DIETHANOLAMINE CONDENSATE                           Date: 09/23/97  
Route: SKIN APPLICATION                                                                                           Time: 09:32:07  
____________________________________________________________________________________________________________________________________

         B6C3F1 MICE FEMALE                        0 MG/KG      15 MG/KG     30 MG/KG                                               
                                                                                                                                    
____________________________________________________________________________________________________________________________________

DISPOSITION SUMMARY                                                                                                                 

  Animals Initially In Study                          55           55           55                                                  

  Scheduled Sacrifice                                  5            5            5                                                  
  Early Deaths                                                                                                                      
  Survivors                                                                                                                         

  Animals Examined Microscopically                     5            5            5                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (1)                                                                           
      Follicle, Cyst                                   1 (100%)                                                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (5)          (5)          (5)                                                 
      Dermis, Skin, Site of Application,                                                                                            
          Inflammation, Chronic Active                              4 (80%)      4 (80%)                                            
      Epidermis, Skin, Site of Application,                                                                                         

a  Number of animals examined microscopically at site and number of animals with lesion                                             

                                                             Page    2                                                              
NTP Experiment-Test: 91014-04         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: CHRONIC                                OLEIC ACID DIETHANOLAMINE CONDENSATE                           Date: 09/23/97  
Route: SKIN APPLICATION                                                                                           Time: 09:32:07  
____________________________________________________________________________________________________________________________________

         B6C3F1 MICE FEMALE                        0 MG/KG      15 MG/KG     30 MG/KG                                               
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
INTEGUMENTARY SYSTEM - CONT                                                                                                         
          Hyperplasia                                               5 (100%)     4 (80%)                                            
      Sebaceous Gland, Skin, Site of Application,                                                                                   
           Hyperplasia                                              5 (100%)     5 (100%)                                           
      Skin, Site of Application, Hyperkeratosis                     2 (40%)      3 (60%)                                            
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             

a  Number of animals examined microscopically at site and number of animals with lesion                                             

                                                             Page    3                                                              
NTP Experiment-Test: 91014-04         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: CHRONIC                                OLEIC ACID DIETHANOLAMINE CONDENSATE                           Date: 09/23/97  
Route: SKIN APPLICATION                                                                                           Time: 09:32:07  
____________________________________________________________________________________________________________________________________

         B6C3F1 MICE MALE                          0 MG/KG      15 MG/KG     30 MG/KG                                               
                                                                                                                                    
____________________________________________________________________________________________________________________________________

DISPOSITION SUMMARY                                                                                                                 

  Animals Initially In Study                          55           55           55                                                  

  Scheduled Sacrifice                                  5            5            5                                                  
  Early Deaths                                                                                                                      
  Survivors                                                                                                                         

  Animals Examined Microscopically                     5            5            5                                                  
   Skin                                               (5)          (5)          (5)                                                 
      Dermis, Skin, Site of Application,                                                                                            
          Inflammation, Chronic Active                              5 (100%)     5 (100%)                                           
      Epidermis, Skin, Site of Application,                                                                                         
          Hyperplasia                                               5 (100%)     5 (100%)                                           
      Epidermis, Skin, Site of Application,                                                                                         
          Inflammation, Suppurative                                              1 (20%)                                            
      Epidermis, Skin, Site of Application,                                                                                         
          Parakeratosis                                             1 (20%)      4 (80%)                                            
      Sebaceous Gland, Skin, Site of Application,                                                                                   
           Hyperplasia                                              5 (100%)     5 (100%)                                           
      Skin, Site of Application, Hyperkeratosis                     4 (80%)      4 (80%)                                            
      Skin, Site of Application, Ulcer                                           1 (20%)                                            
                                                                                                                                    

a  Number of animals examined microscopically at site and number of animals with lesion                                             

                                                             Page    4                                                              
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------